Hypertrophic Cardiomyopathy: Highlights From 2021 & Genetic Testing for HCM
Published: 04 February 2022
-
Views:
1591
-
Likes:
7
-
Views:
1591
-
Likes:
7
-
22m 40sPart 1 | Session 1 Highlights of 2021 Carolyn Ho
Overview
In this hypertrophic cardiomyopathy series, Dr Carolyn Ho, presents two videos discussing highlights of 2021 and genetic testing.
Supported through an educational grant from Bristol Myers Squibb
Learning Objectives
- Recall the efficacy and safety of existing HCM treatments
- Summarise results from ongoing trials with experimental treatments
- Stratify individuals with HCM signs and symptoms for subsequent investigation and / or genetic screening
Target Audience
- Cardiologists
- Heart failure specialists
- Allied healthcare professionals
More from this programme
Part 1
Hypertrophic Cardiomyopathy in Review
Faculty Biographies
Carolyn Ho
Associate Professor
Dr Carolyn Ho is the medical director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital. Dr Ho is also an associate professor of medicine at Harvard Medical School.
Dr Ho’s clinical interests include cardiomyopathy, echocardiography, and cardiovascular genetics.